Curis Reports Second Quarter 2017 Financial Results
03 août 2017 07h00 HE
|
Curis, Inc
LEXINGTON, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017
26 juil. 2017 07h00 HE
|
Curis, Inc
LEXINGTON, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 juil. 2017 16h30 HE
|
Curis, Inc
LEXINGTON, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
UPDATE - Curis to Present at the Jefferies Healthcare Conference
01 juin 2017 12h07 HE
|
Curis, Inc
LEXINGTON, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
Curis to Present at the Jefferies Healthcare Conference
01 juin 2017 07h00 HE
|
Curis, Inc
LEXINGTON, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting
25 mai 2017 07h00 HE
|
Curis, Inc
LEXINGTON, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis Reports First Quarter 2017 Financial Results
04 mai 2017 07h00 HE
|
Curis, Inc
LEXINGTON, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for...
Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017
28 avr. 2017 14h04 HE
|
Curis, Inc
LEXINGTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 avr. 2017 07h00 HE
|
Curis, Inc
LEXINGTON, Mass., April 05, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting
30 mars 2017 13h30 HE
|
Curis, Inc
LEXINGTON, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...